Term
| hepatitis B candidates for tx:3 |
|
Definition
1. HBeAg(+) - DNA>20K
2. HBeAg(-) - DNA>2K
3. cirrhosis - DNA>200 |
|
|
Term
| how long do you continue therapy after HBV DNA undetectable? |
|
Definition
|
|
Term
| first line therapies for HBV: |
|
Definition
|
|
Term
| has direct killing effect on HBV: |
|
Definition
|
|
Term
| tx duration for pegylated interferon: |
|
Definition
|
|
Term
| indication for pegylated interferon: |
|
Definition
| most often deffered until oral agents fail or not tolerated |
|
|
Term
| pegylated interferon not first line in these pts: |
|
Definition
1. mental do
2. BM supression |
|
|
Term
| monitoring HBV therapy: when do you asses tx |
|
Definition
|
|
Term
| contraindications to HCV tx:6 |
|
Definition
1. mental health do
2. DM uncontrolled
3. CVD
4. pergo
5. autoimmune dz
6. renal insuf |
|
|
Term
| prefered medication for HCV: |
|
Definition
pegyated interferon + ribavirin
1. genotype 1 = high dose ribavirin
2. genotype2/3 = low dose ribavirin |
|
|
Term
| tx duration for genotype I |
|
Definition
|
|
Term
| tx duration for genotype II/III |
|
Definition
|
|
Term
| tx response rates for HCV genotypes 1,2,3: |
|
Definition
genotype I = 20-50%
II = 70-80
III = 55-65% |
|
|
Term
| define rapid virologic response for HCV tx: |
|
Definition
| RNA undetectable in 4wks, normal transaminases (95%SVR) |
|
|
Term
| define early virologic tx response for HCV: |
|
Definition
| >2log decrease in RNA or undetectable + normal transaminases at 12 wks |
|
|
Term
| if early virologic response not achieved at 12 wks: |
|
Definition
|
|
Term
| tx duration for HCV/HIV co-infection |
|
Definition
|
|
Term
| define sustained virologic response in HCV tx: |
|
Definition
| undectectable RNA 24wks after therapy completed |
|
|
